Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Why do some cancer survivors struggle with bowel control? new study aims to find out.

NCT ID NCT07573371

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why some people who had surgery for colorectal cancer develop lasting bowel issues like urgency or leakage. Researchers will compare 145 participants with and without these problems using advanced tests. The goal is to identify different types of bowel dysfunction and figure out which treatments might work best for each type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 145 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

During outpatient visits, the treatment responsible doctor will identify eligible patients. Patients will be recruited at the following departments: 1. LARS patients - patient operated for rectal cancer at Department of Surgery, Aarhus University Hospital, with rectal resection with sphincter preservation and primary anastomosis. 2. Watch and wait patients - patient treated for rectal cancer with organ preservation at Aalborg University Hospital or Vejle Hospital. 3. Patients with Faecal Incontinence planned for neuromodulation at Pelvic Floor Unit, Department of Surgery, AUH.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General: * Must be able to read and understand Danish. * All participants must be adults and \>18 years and have full legal capacity. * Assessed by study personnel to have understood the research protocol, being able to comply with investigation procedures as well as ability to come to the hospital at the agreed timepoints, and to complete the trial. Specific inclusion criteria for LARS patients: * Patients operated for rectal cancer with a rectal resection and sphincter preserving surgery at a minimum of three months postop. * If patients have received a temporary protective ileostomy, this should have been reversed for a minimum of three months postop. Specific inclusion criteria for fecal incontinence patients and urge fecal incontinence patients * Patients planned for neuromodulation. * Satisfactory interoperative test results leading to permanent implantation of a pacemaker for sacral nerve modulation. Specific inclusion criteria for "watch and wait" patients: • Rectum/colon cancer patients treated with organ-preserving treatment, i.e., chemotherapy and radiotherapy with a complete clinical and radiological response at a minimum of 12 months posttreatment. Exclusion Criteria: General exclusion criteria * Persons that are not able to understand information * Connective tissue disorders * Parkinson's disease * Non-MRI compatible pacemaker, clips or other metal objects in the body. Patients implanted with a pacemaker for sacral nerve modulation will not undergo MRI postoperatively. * Piercings that cannot be removed before MRI * Claustrophobia * Allergic to latex * Abdominal diameter equal or more than 140 cm * Have other individual factors, in the opinion of the physician/healthcare professional, in which participating is contraindicated * Participation in concomitant clinical trial * Known intestinal obstruction, significant intestinal strictures or perforation. If in doubt about intestinal stricture, the patient will be examined with MRI of the small intestine, colonoscopy or other supplementing examination * Disorders of swallowing * Pregnant women Specific exclusion criterias for LARS patients * History of anastomotic leakage following rectal resection and sphincter preserving therapy * Evidens of local recurrence or dessimination of the cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon carcinoma colorectal carcinoma Encopresis Low Anterior Resection Syndrome rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    ACTIVE_NOT_RECRUITING

    Aalborg, 9220, Denmark

  • Aarhus University Hospital

    RECRUITING

    Aarhus, 8200, Denmark

  • Vejle Hospital

    RECRUITING

    Vejle, 7100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.